参考文献/References:
[1] 中华医学会神经病学分会.中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志,2018,51(9):666-681.
[2] Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patientswith acute ischemic stroke:2019 update to the 2018 guidelines for the early management of acute ischemic stroke:a guideline for healthcare professionals from the american heart association/american stroke association[J]. Stroke, 2019, 50(12): e344-e418.
[3] Berge E, Whiteley W, Audebert H, et al. European Stroke Organisation(ESO)guidelines on intravenous thrombolysis for acute ischaemic stroke[J]. Eur Stroke J, 2021, 6(1): I-LXII.
[4] Gajurel BP, Nepal G, Kharel S, et al.Safety and efficacy of intravenous thrombolysis in acute ischemic stroke patients with a history of intracranial hemorrhage:a systematic review and meta-analysis[Z],2022:107205.
[5] Ehrlich ME, Liang L, Xu H, et al. Intravenous tissue-type plasminogen activator in acute ischemic stroke patients with history of stroke plus diabetes mellitus[J]. Stroke, 2019, 50(6): 1497-1503.
[6] Gumbinger C, Ringleb P, Ippen F, et al. Outcomes of patients with stroke treated with thrombolysis according to prestroke Rankin Scale scores[J]. Neurology, 2019, 93(20): e1834-e1843.
[7] Cooray C, Karlinski M, Kobayashi A, et al. Safety and early outcomes after intravenous thrombolysis in acute ischemic stroke patients with prestroke disability[J]. Int J Stroke, 2021, 16(6): 710-718.
[8] Che FL, Wang AX, Ju Y, et al. Early neurological deterioration in acute ischemic stroke patients after intravenous thrombolysis with alteplase predicts poor 3-month functional prognosis-data from the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China(TIMS-China)[J]. BMC Neurol, 2022, 22(1): 212.
[9] Anderson CS, Huang Y, Lindley RI, et al. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke(ENCHANTED):an international,randomised,open-label,blinded-endpoint,phase 3 trial[J]. Lancet, 2019, 393(10174): 877-888.
[10] Thomalla G, Boutitie F, Ma H, et al. Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging:systematic review and meta-analysis of individual patient data[J]. Lancet, 2020, 396(10262): 1574-1584.
[11] Furlanis G, Aj(ˇoverc)evi('overc)M, Buoite SA, et al. Wake-up stroke: thrombolysis reduces ischemic lesion volume and neurological deficit[J]. J Neurol, 2020, 267(3): 666-673.
[12] Zhang YL, Zhang JF, Wang XX, et al. Wake-up stroke: imaging-based diagnosis and recanalization therapy[J]. J Neurol, 2021, 268(11): 4002-4012.
[13] Seyhan M, Mackenrodt D, Gunreben I, et al. Should IV thrombolysis be given in patients with suspected ischemic stroke but unknown symptom onset and without diffusion-weighted imaging lesion?-results of a case-control study[J]. J Stroke Cerebrovasc Dis, 2020, 29(2): 104515.
[14] Polymeris AA, Curtze S, Erdur H, et al. Intravenous thrombolysis for suspected ischemic stroke with seizure at onset[J]. Ann Neurol, 2019, 86(5): 770-779.
[15] Schlemm L, Braemswig TB, Boutitie F, et al. Cerebral microbleeds and treatment effect of intravenous thrombolysis in acute stroke:an analysis of the WAKE-UP randomized clinical trial[J]. Neurology, 2022, 98(3): e302-e314.
[16] Shahjouei S, Tsivgoulis G, Goyal N, et al. Safety of intravenous thrombolysis among patients taking direct oral anticoagulants:a systematic review and meta-analysis[J]. Stroke, 2020, 51(2): 533-541.
[17] Seiffge DJ, Wilson D, Wu T. Administering thrombolysis for acute ischemic stroke in patients taking direct oral anticoagulants:to treat or how to treat[J]. JAMA Neurol, 2021, 78(5): 515-516.
[18] Barow E, Boutitie F, Cheng B, et al. Functional outcome of intravenous thrombolysis in patients with lacunar infarcts in the WAKE-UP trial[J]. JAMA Neurol, 2019, 76(6): 641-649.
[19] Zivanovic Z, Gubi M, Vlahovic D, et al. Patients with acute lacunar infarction have benefit from intravenous thrombolysis[J]. J Stroke Cerebrovasc Dis, 2019, 28(2): 435-440.
[20] Dodds JA, Xian Y, Sheng S, et al. Thrombolysis in young adults with stroke:findings from get with the guidelines-stroke[J]. Neurology, 2019, 92(24): e2784-e2792.
[21] He L, Xu R, Wang J, et al. Capsular warning syndrome: clinical analysis and treatment[J]. BMC Neurol, 2019, 19(1): 285.
[22] Sun H, Liu Y, Gong P, et al. Intravenous thrombolysis for ischemic stroke with hyperdense middle cerebral artery sign:a meta-analysis[J]. Acta Neurol Scand, 2020, 141(3): 193-201.
[23] Owusu-Guha J, Guha A, Miller PE, et al. Contemporary utilization patterns and outcomes of thrombolytic administration for ischemic stroke among patients with cancer[J]. Int J Stroke, 2021, 16(2): 150-162.
[24] Inohara T, Liang L, Kosinski AS, et al. Thrombolytic therapy in older acute ischemic stroke patients with gastrointestinal malignancy or recent bleeding[J]. Eur Stroke J, 2020, 5(1): 47-55.
[25] Fischer U, Kaesmacher J, Strbian D, et al. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke:an open-label,blinded-outcome,randomised non-inferiority trial[J]. Lancet, 2022, 400(10346): 104-115.
[26] Khatri P. Intravenous thrombolysis before thrombectomy for acute ischaemic stroke[J]. Lancet, 2022, 400(10346): 76-78.
[27] Mitchell PJ, Yan B, Churilov L, et al. Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4·5 h of stroke onset: an open-label, blinded-endpoint,randomised non-inferiority trial[J]. Lancet, 2022, 400(10346): 116-125.
[28] Burgos AM, Saver JL. Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke:meta-analysis of 5 randomized trials[J]. Stroke, 2019, 50(8): 2156-2162.
[29] Warach SJ, An DL, Milling TJ. Tenecteplase thrombolysis for acute ischemic stroke[J]. Stroke, 2020, 51(11): 3440-3451.
[30] Kvistad CE, Næss H, Helleberg BH, et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway(NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint,non-inferiority trial[J]. Lancet Neurol, 2022, 21(6): 511-519.
[31] Menon BK, Buck BH, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada(AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial[J]. Lancet, 2022, 400(10347): 161-169.
[32] Tsivgoulis G, Katsanos AH, Christogiannis C, et al. Intravenous thrombolysis with tenecteplase for the treatment of acute ischemic stroke[J]. Ann Neurol, 2022, 92(3): 349-357.